BioSpace News Archive

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its open-label phase 1 trial of IMU-935, a highly potent and selective inverse agonist of the transcription factor RORγt.

The Honourable Jean-Yves Duclos, Minister of Health, issued the following statement after the tabling of the report by the Auditor General of Canada on the July 1, 2020, to June 30, 2021, performance audit on the Public Health Agency of Canada’s enforcement of mandatory quarantine and testing measures for travellers, to limit the spread of COVID-19 in Canada:

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host a conference call and webcast to discuss their CD73 inhibitor program in multiple myeloma.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2021.

An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering economic benefit from life sciences research and innovation in the UK.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host a live conference call and webcast on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010 tomorrow, Friday, December 10, 2021 at 8:00 a.m. ET.

Johnson & Johnson announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization for the World Health Organization supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above.

Chesapeake Urology physician Andrew Harbin, MD, was the first urologist in Maryland to perform the new, minimally invasive robotic surgical procedure called Aquablation for the effective treatment of BPH/enlarged prostate symptoms.

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced financial results for the 2021 fiscal year ended July 31, 2021.

CANbridge Pharmaceuticals, Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development, and commercialization of transformative therapies, was officially listed on the Main Board of the Stock Exchange of Hong Kong Limited.